Advertisement

Cancer Chemotherapy and Pharmacology

, Volume 29, Issue 5, pp 379–384 | Cite as

Pharmacokinetics and toxicity of the antitumour agentN-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse

  • James W. Paxton
  • Deborah Young
  • Sean M. H. Evans
  • Philip Kestell
  • Iain G. C. Robertson
  • Eain M. Cornford
Original Articles Acridine-Carboxamide, Pharmacokinetics, Toxicity

Summary

The pharmacokinetics, tissue distribution and toxicity of the antitumour agentN-[2-(dimethylamino)ethyl]acridine-4-carboxamide(AC) were studied after i.v. administration to mice. Over the dose range of 9–121 μmol/kg (3–40 mg/kg), AC displayed linear kinetics with the following model-independent parameters: clearance (C), 21.0±1.9 l h−1 kg−1; steady-state volume of distribution (Vss), 11.8±1.4 l/kg; and mean residence time (MRT), 0.56±0.02 h. The plasma concentration-time profiles for AC fitted a two-compartment model with the following parameters:Cc, 19.4±2.3 l h−1 kg−1; Vc, 7.08±1.06 l/kg;t1/2α 13.1±3.5 min; andt1/2Z, 1.60±0.65 h. AC displayed moderately high binding in healthy mouse plasma, giving a free fraction of 15.9%–25.3% over the drug concentration range of 1–561 μM. After the i.v. administration of 30 μmol/kg [3H]-AC, high radioactivity concentrations were observed in all tissues (especially the brain and kidney), showing a hight1/2c value (37–59 h). At 2 min (first blood collection), the AC concentration as measured by high-performance liquid chromatography (HPLC) comprised 61% of the plasma radioactivity concentration (expressed as AC equivalents/l). By 48 h, 73% of the dose had been eliminated, with 26% and 47% of the delivered drug being excreted by the urinary and faecal routes, respectively; <1% of the total dose was excreted as unchanged AC in the urine. At least five distinct radiochemical peaks were distinguishable by HPLC analysis of plasma extracts, with some similar peaks appearing in urine. The 121-μmol/kg dose was well tolerated by mice, with sedation being the only obvious side effect and no significant alterations in blood biochemistry or haematological parameters being recorded. After receiving a dose of 152 μmol/kg, all mice experienced clonic seizures for 2 min (with one death occuring) followed by a period of sedation that lasted for up to 2h. No leucopenia occurred, but some mild anaemia was noted. There was no significant change in blood biochemistry. A further 20% increase in the i.v. dose (to 182 μmol/kg) resulted in mortality, with death occurring within 2 min of AC administration.

Keywords

Dimethylamino Mean Residence Time Radioactivity Concentration Clonic Seizure Blood Biochemistry 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Arlin Z (1983) Current status of amsacrine combination chemotherapy programs in acute leukaemia. Cancer Treat Rep 67: 967Google Scholar
  2. 2.
    Baguley BC, Denny WA, Atwell GJ, Finlay GJ, Rewcastle GW, Twigden SJ, Wilson WR (1984) Synthesis, antitumour activity and DNA binding properties of a new derivative of amsacrineN,5-dimethyl-9-(2-methoxy-4-methylsulfonylamino)phenylamino-4-acridinecarboxamide. Cancer Res 44: 3245Google Scholar
  3. 3.
    Boxenbaum H (1982) Interspecies scaling, allometry, physiological time and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10: 201Google Scholar
  4. 4.
    Cornford EM, Young D, Paxton JW (1991) A comparison of brain and liver penetration of acridine antitumor drugs. Cancer Chemother Pharmacol (in press)Google Scholar
  5. 5.
    Finlay GJ, Baguley BC (1989) Selectivity ofN-[2-(dimethyl-amino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro. Eur J Cancer Clin Oncol 25: 271Google Scholar
  6. 6.
    Finlay GJ, Rewcastle GW, Baguley BC, Denny WA (1987) Potential antitumour agents: 50. In vivo solid tumour activity of derivatives ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem 30: 664Google Scholar
  7. 7.
    Gibaldi M, Perrier D (1982) Noncompartment analysis based on statistical moment theory. In: Gibaldi M, Perrier D (eds) Pharmacokinetics. Marcel Dekker, New YorkGoogle Scholar
  8. 8.
    Greig MH (1987) Chemotherapy of brain metastases: current status. Cancer Treat Rep 11: 157Google Scholar
  9. 9.
    Hardy JR, Harvey VJ, paxton JW, Evans PC, Smith S, Grove W, Grillo-Lopez AJ, Baguley BC (1988) A phase I trial of the amsacrine analog 9-[[2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino]-N,5-dimethyl-4-acridine-carboxamide (CI-921). Cancer Res 48: 6493Google Scholar
  10. 10.
    Holford NHG (1985) MKMODEL, a modelling tool for micro-computers — a pharmacokinetic evaluation and comparison with standard computer programs (abstract). Clin Exp Pharmacol [Suppl 9]: 95Google Scholar
  11. 11.
    Huang JD (1983) Errors in estimating the unbound fraction of drugs due to volume shifts in equilibrium dialysis. J Pharm Sci 72: 1368Google Scholar
  12. 12.
    Kestell P, Paxton JW, Evans PC, Young D, Jurlina JL, Robertson IGC, Baguley BC (1990) Disposition of amsacrine and its analogue 9-({2-methoxy-4-[(methylsulfonyl)amino]phenyl}amino)-N-5-dimethyl-4-acridine-carboxamide (CI-921) in plasma, liver and Lewis lung tumors in mice. Cancer Res 50: 503Google Scholar
  13. 13.
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265Google Scholar
  14. 14.
    Paxton JW (1983) Alpha1-acid glycoprotein and binding of basic drugs. Methods Find Exp Clin Pharmacol 25: 353Google Scholar
  15. 15.
    Tozer TN, Gambertoglio JG, Furst DE, Avery DS, Holford NHG (1983) Volume shifts and protein binding estimates using equilibrium dialysis; application to prednisolone binding in humans. J Pharm Sci 72: 1442Google Scholar
  16. 16.
    Young D, Evans PC, Paxton JW (1990) Quantitation of the antitumour agentN-[2-(dimethylamino)ethyl]acridine-4-carboxamide in plasma by high performance liquid chromatography. J Chromatogr Biomed Appl 528: 385Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • James W. Paxton
    • 1
  • Deborah Young
    • 1
  • Sean M. H. Evans
    • 1
  • Philip Kestell
    • 2
  • Iain G. C. Robertson
    • 1
  • Eain M. Cornford
    • 3
  1. 1.Department of Pharmacology and Clinical PharmacologyUniversity of Auckland School of MedicineAucklandNew Zealand
  2. 2.Cancer Research LaboratoryUniversity of Auckland School of MedicineAnckland
  3. 3.Veterans AdministrationWest Los Angeles Medical CenterUSA

Personalised recommendations